A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine |
| |
Authors: | Lidia Savi Stefano Omboni Carlo Lisotto Giorgio Zanchin Michel D Ferrari Dario Zava Lorenzo Pinessi |
| |
Institution: | 1.Neurology II, Headache Center, Department of Neuroscience, University of Turin, Via Cherasco, 15, 10126 Turin, Italy ;2.Italian Institute of Telemedicine, Varese, Italy ;3.Ospedale Civile, San Vito al Tagliamento, Italy ;4.Department of Neurology, University of Padova, Padua, Italy ;5.Leiden Centre for Translational Neuroscience, Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands ;6.Istituto Lusofarmaco d’Italia, Milan, Italy |
| |
Abstract: | The objective of this study was to assess patient satisfaction with acute treatment of migraine with frovatriptan or rizatriptan by preference questionnaire. 148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or rizatriptan 10 mg treating 1–3 attacks. The study had a multicenter, randomized, double-blind, cross-over design, with treatment periods lasting <3 months. At the end of the study, patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints were pain-free and pain relief episodes at 2 h, and recurrent and sustained pain-free episodes within 48 h. 104 of the 125 patients (83%, intention-to-treat population) expressed a preference for a triptan. The average preference score was not significantly different between frovatriptan (2.9 ± 1.3) and rizatriptan (3.2 ± 1.1). The rates of pain-free (33% frovatriptan vs. 39% rizatriptan) and pain relief (55 vs. 62%) episodes at 2 h were not significantly different between the two treatments. The rate of recurrent episodes was significantly (p < 0.001) lower under frovatriptan (21 vs. 43% rizatriptan). No significant differences were observed in sustained pain-free episodes (26% frovatriptan vs. 22% rizatriptan). The number of patients with adverse events was not significantly different between rizatriptan (34) and frovatriptan (25, p = NS). The results suggest that frovatriptan has a similar efficacy to rizatriptan, but a more prolonged duration of action.Electronic supplementary materialThe online version of this article (doi:10.1007/s10194-010-0243-y) contains supplementary material, which is available to authorized users. |
| |
Keywords: | Migraine Frovatriptan Rizatriptan Patient preference |
本文献已被 SpringerLink 等数据库收录! |
|